Donor lymphocyte infusion followed by pentostatin, cyclophosphamide and rituximab therapy is effective for relapsed chronic lymphocytic leukemia after allogeneic stem cell transplant

摘要

Fludarabine-refractory chronic lymphocytic leukemia (CLL) has a poor prognosis [1]. Pentostatin, cyclophosphamide and rituximab (PCR) therapy is one of the salvage regimens used to treat fludarabine-refractory CLL [2]. In addition, alloge-neic stem cell transplant (SCT) can be curative for refractory CLL [3]. Compared with a myeloablative conditioning (MAC) regimen, a reduced-intensity conditioning (RIC) regimen tends to decrease treatment-related mortality and increase overall survival after SCT [4].